[Omalizumab for therapy-resistant chronic urticaria with angioedema].
A 29-old man presented with severe chronic urticaria and angioedema. Routine evaluation including history, laboratory parameters and imaging procedures did not reveal any pathologic findings. We tried combined therapy regimes including high-dose systemic corticosteroids and antihistamines, leukotriene antagonist, cyclosporine and antibiotics. Because of a poor response and dramatic escalation of symptoms, we initiated therapy with omalizumab resulting in the complete remission of the chronic urticaria after two weeks.
Korkmaz
H
H
Hautklinik der Heinrich-Heine-Universität, Moorenstr. 5 , 40225, Düsseldorf.
Eigelshoven
S
S
Homey
B
B
D000328:Adult; D000799:Angioedema / Q000188:drug therapy* / Q000276:immunology; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007964:Leukocytosis / Q000188:drug therapy / Q000276:immunology; D017336:Loratadine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D000069444:Omalizumab; D011239:Prednisolone / Q000627:therapeutic use
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039563:Histamine H1 Antagonists, Non-Sedating; D000069444:Omalizumab; D007073:Immunoglobulin E; D017336:Loratadine; D011239:Prednisolone; C121345:desloratadine